PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology firm, announced that CEO David H. Mack, Ph.D., will join a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, scheduled for November 29 – December 1, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology firm, announced that CEO David H. Mack, Ph.D., will join a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, scheduled for November 29 – December 1, 2022. The conference will focus on PMV Pharma's pioneering work in small molecule, tumor-agnostic therapies targeting p53, a protein associated with roughly half of all cancers. Investors will also have opportunities for one-on-one meetings during the event.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was +5.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will also be available to meet one-on-one with institutional investors at the conference. Details on the fireside chat can be found below.
5th Annual Evercore ISI HealthCONx Conference
| Date: | Tuesday, November 29, 2022 |
| Time: | 3:05 – 3:25 PM ET |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contacts
Investor Contact:
Winston Kung
PMV Pharmaceuticals, Inc.
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.